RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Kukje Pharma Co Stock

Kukje Pharma Co Revenue 2024

Kukje Pharma Co Revenue

135.37 B KRW

Ticker

002720.KS

ISIN

KR7002720001

In 2024, Kukje Pharma Co's sales reached 135.37 B KRW, a 6.94% difference from the 126.58 B KRW sales recorded in the previous year.

The Kukje Pharma Co Revenue history

YEARREVENUE (undefined KRW)GROSS MARGIN (%)
2023135.3749,66
2022126.5849,97
2021119.7545,49
2020130.449,70
2019111.1247,68
2018107.6845,33
2017123.3141,74
2016120.6844,56
2015117.6444,86
2014122.4338,53
2013120.4639,66
2012126.7735,03
2011104.8642,72
2010132.0544,31
2009122.5749,06
2008121.6455,56
2007103.7655,63
200697.2759,04
200590.7655,38
200495.2949,22

Kukje Pharma Co Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Kukje Pharma Co, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Kukje Pharma Co from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Kukje Pharma Co’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Kukje Pharma Co. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Kukje Pharma Co’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Kukje Pharma Co’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Kukje Pharma Co’s growth potential.

Kukje Pharma Co Revenue, EBIT and net profit per share

DateKukje Pharma Co RevenueKukje Pharma Co EBITKukje Pharma Co Net Income
2023135.37 B KRW-1.99 B KRW-8.42 B KRW
2022126.58 B KRW5.27 B KRW3.56 B KRW
2021119.75 B KRW-1.68 B KRW-1.56 B KRW
2020130.4 B KRW6.04 B KRW2.2 B KRW
2019111.12 B KRW5.57 B KRW-4.76 B KRW
2018107.68 B KRW3.29 B KRW2.19 B KRW
2017123.31 B KRW2.56 B KRW1.09 B KRW
2016120.68 B KRW3.97 B KRW773 M KRW
2015117.64 B KRW2.1 B KRW-5.94 B KRW
2014122.43 B KRW-1.42 B KRW-6.93 B KRW
2013120.46 B KRW1.23 B KRW2.13 B KRW
2012126.77 B KRW-14.71 B KRW-18.94 B KRW
2011104.86 B KRW2.6 B KRW928 M KRW
2010132.05 B KRW9.65 B KRW4.24 B KRW
2009122.57 B KRW8.75 B KRW6.86 B KRW
2008121.64 B KRW13.87 B KRW6.6 B KRW
2007103.76 B KRW12.68 B KRW6.23 B KRW
200697.27 B KRW13.31 B KRW6.14 B KRW
200590.76 B KRW10.44 B KRW5.16 B KRW
200495.29 B KRW10.64 B KRW5.1 B KRW

Kukje Pharma Co stock margins

The Kukje Pharma Co margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Kukje Pharma Co. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Kukje Pharma Co.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Kukje Pharma Co's sales revenue. A higher gross margin percentage indicates that the Kukje Pharma Co retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Kukje Pharma Co's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Kukje Pharma Co's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Kukje Pharma Co's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Kukje Pharma Co. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Kukje Pharma Co's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Kukje Pharma Co Margin History

Kukje Pharma Co Gross marginKukje Pharma Co Profit marginKukje Pharma Co EBIT marginKukje Pharma Co Profit margin
202349.66 %-1.47 %-6.22 %
202249.97 %4.17 %2.81 %
202145.49 %-1.4 %-1.3 %
202049.7 %4.63 %1.69 %
201947.68 %5.01 %-4.28 %
201845.33 %3.05 %2.04 %
201741.74 %2.08 %0.89 %
201644.56 %3.29 %0.64 %
201544.86 %1.78 %-5.05 %
201438.53 %-1.16 %-5.66 %
201339.66 %1.02 %1.76 %
201235.03 %-11.6 %-14.94 %
201142.72 %2.48 %0.89 %
201044.31 %7.31 %3.21 %
200949.06 %7.14 %5.6 %
200855.56 %11.41 %5.43 %
200755.63 %12.22 %6 %
200659.04 %13.69 %6.32 %
200555.38 %11.5 %5.69 %
200449.22 %11.16 %5.35 %

Kukje Pharma Co Aktienanalyse

What does Kukje Pharma Co do?

Kukje Pharma Co ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Revenue Details

Understanding Kukje Pharma Co's Sales Figures

The sales figures of Kukje Pharma Co originate from the total revenue accrued from goods sold or services provided during a specific time period. These numbers are a direct reflection of the company’s ability to translate its products or services into revenue, indicating the demand and market presence.

Year-to-Year Comparison

Analyzing Kukje Pharma Co’s yearly sales data offers insights into the company’s growth and stability. An increase in sales suggests a growing demand for its offerings, efficient marketing, or expansion into new markets. Conversely, a decline might indicate market saturation, increased competition, or less effective strategies.

Impact on Investments

Investors often scrutinize Kukje Pharma Co's sales data to evaluate its financial health and growth prospects. Consistent sales growth can be a promising indicator of the company’s profitability and potential return on investment, influencing stock prices and investor confidence.

Interpreting Sales Fluctuations

Increases in Kukje Pharma Co’s sales indicate market growth, innovation, or effective marketing, often leading to a surge in stock prices. A decline, however, can signal challenges requiring strategic adjustments to enhance market share and profitability.

Frequently Asked Questions about Kukje Pharma Co stock

How much revenue did Kukje Pharma Co generate this year?

Kukje Pharma Co has achieved a revenue of 135.37 B KRW this year.

How much was the turnover of the company Kukje Pharma Co compared to the previous year?

The revenue of Kukje Pharma Co has increased by 6.94% increased compared to the previous year.

What does revenue mean for investors?

The revenue of a company is an important indicator of its financial performance and attractiveness for investors.

Which factors influence the revenue of Kukje Pharma Co?

The revenue of Kukje Pharma Co is influenced by various factors, including the demand for its products and services, market conditions, and prices.

How is the revenue of Kukje Pharma Co measured?

Revenue is typically measured in units referring to the sale of goods and services provided by the company.

How does an increase in sales affect investments?

An increase in revenue can prompt investors to invest more money in the company as it serves as a positive signal for its financial performance and growth prospects.

What are the possible risks associated with a declining revenue?

A decline in revenue can prompt investors to invest less money in the company, as it is a negative signal for its financial performance and growth prospects.

Why is the sales revenue of Kukje Pharma Co so important for investors?

The revenue of Kukje Pharma Co is an important indicator of financial performance and attractiveness for investors.

What strategic measures can a company take to increase revenue?

A company can take various strategic measures to increase revenue, including developing new products and services, introducing new pricing models, and expanding into new markets.

How much dividend does Kukje Pharma Co pay?

Over the past 12 months, Kukje Pharma Co paid a dividend of 26.68 KRW . This corresponds to a dividend yield of about 0.49 %. For the coming 12 months, Kukje Pharma Co is expected to pay a dividend of 0 KRW.

What is the dividend yield of Kukje Pharma Co?

The current dividend yield of Kukje Pharma Co is 0.49 %.

When does Kukje Pharma Co pay dividends?

Kukje Pharma Co pays a quarterly dividend. This is distributed in the months of January, January, January, January.

How secure is the dividend of Kukje Pharma Co?

Kukje Pharma Co paid dividends every year for the past 0 years.

What is the dividend of Kukje Pharma Co?

For the upcoming 12 months, dividends amounting to 0 KRW are expected. This corresponds to a dividend yield of 0 %.

In which sector is Kukje Pharma Co located?

Kukje Pharma Co is assigned to the 'Health' sector.

Wann musste ich die Aktien von Kukje Pharma Co kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Kukje Pharma Co from 4/11/2019 amounting to 29.412 KRW, you needed to have the stock in your portfolio before the ex-date on 12/27/2018.

When did Kukje Pharma Co pay the last dividend?

The last dividend was paid out on 4/11/2019.

What was the dividend of Kukje Pharma Co in the year 2023?

In the year 2023, Kukje Pharma Co distributed 0 KRW as dividends.

In which currency does Kukje Pharma Co pay out the dividend?

The dividends of Kukje Pharma Co are distributed in KRW.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Kukje Pharma Co

Our stock analysis for Kukje Pharma Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Kukje Pharma Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.